Brian D Lehmann

List of Publications by Year
in descending order

63	12,256	101384 36	128067 60
papers	citations	h-index	g-index

67	67	67	18018
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 2011, 121, 2750-2767.	3.9	4,137
2	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	1.9	1,858
3	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 2016, 11, e0157368.	1.1	975
4	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	3.2	597
5	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	7.7	413
6	Senescence-Associated Exosome Release from Human Prostate Cancer Cells. Cancer Research, 2008, 68, 7864-7871.	0.4	391
7	Identification and use of biomarkers in treatment strategies forÂtripleâ€negative breast cancer subtypes. Journal of Pathology, 2014, 232, 142-150.	2.1	354
8	Subtyping of tripleâ€negative breast cancer: Implications for therapy. Cancer, 2015, 121, 8-16.	2.0	280
9	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research, 2014, 16, 406.	2.2	267
10	New Strategies for Triple-Negative Breast Cancerâ€"Deciphering the Heterogeneity. Clinical Cancer Research, 2014, 20, 782-790.	3.2	242
11	TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Informatics, 2012, 11, CIN.S9983.	0.9	201
12	BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition. Clinical Cancer Research, 2013, 19, 6696-6702.	3.2	160
13	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene, 2008, 27, 4086-4095.	2.6	147
14	Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research, 2013, 19, 2723-2733.	3.2	146
15	Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e31-e39.	1.8	108
16	Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast, 2015, 24, S36-S40.	0.9	108
17	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	3.2	104
18	A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS ONE, 2015, 10, e0125482.	1.1	99

#	Article	IF	Citations
19	Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer. Cancer Research, 2014, 74, 3180-3194.	0.4	97
20	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle, 2012, 11, 4579-4588.	1.3	91
21	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 2111-2123.	3.2	91
22	Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle, 2008, 7, 1745-1762.	1.3	89
23	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications, 2021, 12, 6276.	5.8	89
24	A Dominant Role for p53-Dependent Cellular Senescence in Radiosensitization of Human Prostate Cancer Cells. Cell Cycle, 2007, 6, 595-605.	1.3	87
25	Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research, 2013, 15, 201.	2.2	80
26	Multi-perspective quality control of Illumina exome sequencing data using QC3. Genomics, 2014, 103, 323-328.	1.3	79
27	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation, 2007, 47, 64-103.	2.9	77
28	Targeting Mutant p53 in Human Tumors. Journal of Clinical Oncology, 2012, 30, 3648-3650.	0.8	66
29	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Research, 2010, 12, R41.	2.2	63
30	The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. International Journal of Genomics, 2017, 2017, 1-9.	0.8	59
31	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer, 2016, 16, 143.	1.1	55
32	Comparative Study of Exome Copy Number Variation Estimation Tools Using Array Comparative Genomic Hybridization as Control. BioMed Research International, 2013, 2013, 1-7.	0.9	47
33	Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Research, 2014, 16, R69.	2.2	46
34	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine, 2020, 12, .	5.8	46
35	Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1088-H1095.	1.5	41
36	Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells. Oncotarget, 2011, 2, 610-626.	0.8	41

#	Article	IF	Citations
37	Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget, 2015, 6, 21353-21368.	0.8	35
38	RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library. BioMed Research International, 2015, 2015, 1-9.	0.9	34
39	Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Research, 2016, 76, 4850-4860.	0.4	33
40	SPARCL1 suppresses metastasis in prostate cancer. Molecular Oncology, 2013, 7, 1019-1030.	2.1	32
41	Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nature Communications, 2021, 12, 5184.	5.8	30
42	Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data. Briefings in Bioinformatics, 2016, 17, 224-232.	3.2	29
43	Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer, 2017, 17, 241.	1.1	27
44	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes, 2018, 9, 29.	1.0	21
45	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.9	20
46	Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle, 2008, 7, 1262-1268.	1.3	16
47	Estimating relative mitochondrial DNA copy number using high throughput sequencing data. Genomics, 2017, 109, 457-462.	1.3	16
48	RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. International Journal of Genomics, 2016, 2016, 1-10.	0.8	15
49	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biology and Therapy, 2007, 6, 1176-1181.	1.5	13
50	Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death and Disease, 2021, 12, 745.	2.7	13
51	Detection of internal exon deletion with exon Del. BMC Bioinformatics, 2014, 15, 332.	1.2	12
52	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Molecular Cancer Research, 2019, 17, 1842-1853.	1.5	11
53	Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS ONE, 2020, 15, e0231711.	1.1	11
54	Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. Oncotarget, 2019, 10, 133-151.	0.8	10

#	Article	IF	Citations
55	LR Hunting: A Random Forest Based Cellâ€“Cell Interaction Discovery Method for Single-Cell Gene Expression Data. Frontiers in Genetics, 2021, 12, 708835.	1.1	9
56	Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 1005-1005.	0.8	8
57	Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. Cancers, 2021, 13, 1154.	1.7	7
58	A Data Similarity-Based Strategy for Meta-analysis of Transcriptional Profiles in Cancer. PLoS ONE, 2013, 8, e54979.	1.1	4
59	Practicality of identifying mitochondria variants from exome and RNAseq data. BMC Bioinformatics, 2015, 16, P6.	1.2	3
60	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
61	Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes. , 2019, , .		0
62	Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype. Cancer Research, 2022, 82, PD3-04-PD3-04.	0.4	0
63	Abstract P5-09-01: Using isogenic model systems to determine mechanisms regulating mutant p53 protein stability in breast cancer cells. Cancer Research, 2022, 82, P5-09-01-P5-09-01.	0.4	0